-1 	|BT| (S (NP (NN Simvastatin)) (VP (VP (VBZ induces) (NP (NN apoptosis) (JJ human) (NN colon) (NN cancer) (NN cell) (NN tumor) (NN xenograft))) (, ,) (VP (VBZ attenuates) (NP (JJ colitis-associated) (NN colon) (NN cancer) (NN mouse))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 41:A11 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 92:E04.936.764 93:A01.941.875 754:D02.455.426.559.847.638.400.900|ES| 2:1 7:1 18:1 19:1 36:1 52:1 89:1 94:1 113:1 214:1 265:1 410:1 2423:1 2961:1
-1 	|BT| (S (NP (NP (NN Sodium) (NN butyrate)) (PRN (-LRB- -LRB-) (NP (NN NaB)) (-RRB- -RRB-))) (VP (VP (VBZ inhibits) (NP (NN proliferation))) (, ,) (VP (VBZ stimulates) (NP (NN apoptosis))) (, ,) (VP (VBZ promotes) (NP (NN differentiation) (JJ human) (NN colon) (NN cancer) (NN cell)) (PP (IN along) (NP (JJ absorptive) (NN phenotype)))))) |ET| |BS|39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 80:G05.695 122:C14.280.383 1075:D02.241.081.114.750|ES| 2:1 10:1 14:1 18:1 19:1 36:1 89:1 94:1 113:1 215:1 236:1 298:1 299:1 615:1 2666:1 2962:1 3758:1 3759:1 3760:1 3761:1
-1 	|BT| (S (NP (NNP Sorafenib)) (VP (VBZ sensitizes) (NP (JJ hepatocellular) (ADJP (NN carcinoma) (NN cell) (JJ physiological)) (JJ apoptotic) (NN stimulus)))) |ET| |BS|39:G04.299.139.160 104:C04.557.470.200.025.255 230:G04|ES| 19:1 94:1 303:1 304:1 2062:1 2223:1 2730:1 3210:1 3762:1
-1 	|BT| (NP (NP (NP (NN SRJ09)) (PRN (-LRB- -LRB-) (NP (CD 3,19) (: -) (-LRB- -LRB-) (NN 2-bromobenzylidene) (-RRB- -RRB-) (NN andrographolide)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ semisynthetic) (NN andrographolide)) (PRN (-LRB- -LRB-) (NP (NN AGP)) (-RRB- -RRB-))) (NP (NN derivative)) (, ,) (VP (VBN shown) (VP (VBP induce) (NP (NN G1) (NN cell) (NN cycle) (NN arrest)) (NP (ADVP (RB eventually)) (NP (NN apoptosis) (NN breast) (NN colon) (NN cancer) (NN cell) (NN line)))))) |ET| |BS|10:A01.236 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 94:A11.251.210 1076:G04.299.134.109.249|ES| 2:1 10:1 14:1 18:1 19:1 23:1 89:1 94:1 113:1 237:1 243:1 264:1 601:1 602:1 670:1 2813:1 3763:1 3764:1 3765:1 3766:1 3767:1 3768:1 3769:1
-1 	|BT| (NP (NP (NN Sulindac) (NN reversal) (JJ 15-PGDH-mediated) (NN resistance) (NN colon) (NN tumor) (NN chemoprevention) (NNS NSAIDs))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 251:D02.455.426.559.847.486.875 253:E02.319.162 796:D27.505.696.663.850.014.040.500|ES| 7:1 19:1 113:1 870:1 1094:1 2965:1 2966:1 3770:1 3771:1
-1 	|BT| (NP (NP (NP (JJ Suppressive) (NN effect)) (NP (ADJP (RB enzymatically) (VBN modified)) (NN isoquercitrin) (JJ phenobarbital-induced) (NN liver) (NN tumor) (NN promotion) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650|ES| 7:1 19:1 75:1 836:1 849:1 2335:1 2337:1 3772:1 3773:1 3774:1 3775:1
-1 	|BT| (S (NP (JJ Suppressive) (NN effect) (NN liver) (JJ tumor-promoting) (NN activity) (NN rat)) (VP (VBN subjected) (NP (JJ combined) (NN administration) (JJ phenobarbital) (NN piperonyl) (NN butoxide)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 756:D03.383.742.698.253.650 1077:D03.383.246.118.600|ES| 19:1 75:1 164:1 399:1 836:1 849:1 2575:1 2685:1 3267:1 3772:1 3776:1 3777:1 3778:1
-1 	|BT| (S (NP (NN Survivin) (NN overexpression)) (VP (VBN associated) (NP (NP (JJ poor) (NN prognosis) (JJ human) (JJ gastric) (NN cancer)) (, ,) (NP (NN target) (JJ gastric) (NN cancer) (NN therapy))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 159:I01.880.735.634 163:E01.789|ES| 2:1 18:1 19:1 36:1 86:1 130:1 152:1 160:1 169:1 544:1 545:1 3779:1
-1 	|BT| (NP (NP (NP (NN Susceptibility) (NN aflatoxin) (JJ B1-related) (JJ primary) (JJ hepatocellular) (NN carcinoma) (NN mouse)) (ADJP (JJ human)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 401:C23.550.291.687 1078:D03.383.663.283.119.075|ES| 19:1 36:1 52:1 303:1 304:1 344:1 2214:1 3780:1 3781:1
-1 	|BT| (NP (NP (JJ Synergistic) (JJ chemopreventive) (NN effect) (NN nobiletin) (NN atorvastatin) (NN colon) (NN carcinogenesis))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 624:D27.505.696.706.018|ES| 19:1 75:1 113:1 207:1 1946:1 3782:1 3783:1 3784:1
-1 	|BT| (SINV (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (S (VP (VBG finding) (VP (VBP demonstrate) (SBAR (S (NP (NN pectolinarigenin)) (VP (MD may) (NP (NP (NN candidate) (NN osteosarcoma) (NN intervention)) (VP (VBN linked) (NP (NP (NN STAT3)) (NN signaling) (JJ inhibitory) (NN activity))))))))))) |ET| |BS|69:G02.111.087.800 82:D12.644.360.024.342.300 447:C04.557.450.565.575.650|ES| 2:1 19:1 106:1 195:1 251:1 399:1 491:1 502:1 927:1 1243:1 1363:1 1537:1 1538:1 1562:1 2429:1 2785:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (VP (VBP provide) (NP (JJ direct) (NN evidence) (JJ decorin-mediated) (NN inhibition) (JJ colorectal) (NN cancer) (NN growth) (NN migration) (NN interaction) (NN stabilization) (NN E-cadherin))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 45:G07.700.320.249 613:D12.776.395.550.200.200 708:D12.776.395.650.750.625|ES| 2:1 17:1 18:1 19:1 38:1 101:1 102:1 103:1 514:1 618:1 711:1 1537:1 1538:1 1891:1 2267:1 3785:1 3786:1
-1 	|BT| (S (NP (NN Tandutinib)) (VP (VBZ inhibits) (S (NP (NN Akt/mTOR) (NN signaling) (NN pathway)) (VP (VBP inhibit) (NP (NN colon) (NN cancer) (NN growth)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 378:D08.811.913.696.620.682.700.755|ES| 18:1 19:1 102:1 113:1 195:1 383:1 615:1 1370:1 2819:1 3787:1
-1 	|BT| (NP (NP (NP (NN Targeting) (NN cyclooxygenase-2) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN prevention) (NN treatment)) (JJ intestinal) (NP (NN cancer)))) |ET| |BS|24:D08.811.600.720.750 52:E02 64:D08.811.913.696.620.682.725.400.009.300 101:C04.588.274.476.411|ES| 18:1 19:1 61:1 102:1 109:1 184:1 185:1 186:1 546:1 1474:1 2100:1
-1 	|BT| (FRAG (NP (NP (DT The) (NN aim) (NN work)) (VBP characterize) (NP (NP (NN effect) (NN CAPE) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CYP)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (VBN involved) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NP (NN metabolism) (NN initiation) (NN stage) (NN chemical) (NN hepatocarcinogenesis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 445:I03.946 554:D02.654.442.200 898:G03.495 1079:D08.244.453|ES| 2:1 10:1 14:1 19:1 75:1 637:1 691:1 774:1 900:1 1129:1 1546:1 1567:1 1875:1 1952:1 2124:1 2252:1 2332:1 2549:1 3163:1 3788:1 3789:1
-1 	|BT| (FRAG (NP (NP (DT The) (JJ angiogenic) (NN inducer) (NN CYR61)) (PP (RB differentially) (NP (NP (NP (JJ overexpressed) (NN breast) (NN cancer) (NN cell)) (VP (VBG exhibiting) (NP (NP (JJ high) (NN level) (NN Heregulin)) (PRN (-LRB- -LRB-) (NP (NN HRG)) (-RRB- -RRB-))))) (, ,) (NP (NN growth) (NN factor)) (NP (ADVP (RB closely)) (NP (VBN associated) (JJ metastatic) (NN breast) (NN cancer) (NN phenotype))))))) |ET| |BS|10:A01.236 41:A11 80:G05.695 113:C04.697.650 175:J01.897.280.500.269 1080:D12.644.276.860.550.750 1081:D12.644.276.860.550|ES| 2:1 10:1 14:1 18:1 19:1 23:1 25:1 94:1 102:1 169:1 178:1 185:1 236:1 249:1 337:1 691:1 855:1 1139:1 3790:1 3791:1 3792:1 3793:1 3794:1 3795:1
-1 	|BT| (S (NP (DT The) (JJ anti-tumor) (NN effect) (NN thymoquinone)) (ADVP (RB also)) (VP (VP (VBD investigated) (NP (NN tumor) (NN xenograft) (NN mouse) (NN model) (NN colon))) (, ,) (NP (NN prostate) (, ,) (JJ pancreatic) (NN lung) (NN cancer)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 34:A05.360.444.575 46:A03.556.124.526.356 92:E04.936.764 93:A01.941.875 608:A03.734|ES| 2:1 5:1 7:1 18:1 19:1 52:1 72:1 75:1 77:1 113:1 265:1 328:1 403:1 467:1 691:1 3677:1 3796:1
-1 	|BT| (S (NP (DT The) (NN blockade) (NN 5-LOX)) (VP (VP (VBZ inhibits) (NP (NN colon) (NN cancer) (NN cell) (NN proliferation)) (ADVP (FW vitro) (FW vivo))) (SBAR (S (VP (MD may) (VP (VB prove) (NP (JJ beneficial) (JJ chemopreventive) (NN therapy) (NN colon) (NN cancer)))))))) |ET| |BS|52:E02 122:C14.280.383 183:G04.299.233.750 548:D08.811.682.664.500.848|ES| 18:1 19:1 94:1 113:1 130:1 216:1 299:1 378:1 491:1 615:1 691:1 984:1 1946:1 2669:1 3390:1 3797:1
-1 	|BT| (NP (NP (NP (DT The) (VBN cooked) (NN meat)) (VBN derived) (JJ genotoxic) (NN carcinogen) (JJ 2-amino-3-methylimidazo) (PRN (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-)) (NN pyridine) (JJ potent) (JJ hormone-like) (NN activity)) (: :) (NP (NP (JJ mechanistic) (NN support) (NN role)) (NN breast) (NN cancer))) |ET| |BS|15:F01.829.316.616 161:D06.472 279:D27.888.569.100 744:D03.383.725 1082:J01.576.423.200.200 1083:G07.203.300.600|ES| 18:1 19:1 22:1 23:1 31:1 104:1 399:1 691:1 1364:1 1373:1 1378:1 1721:1 1890:1 2125:1 2639:1 2640:1 3329:1 3581:1 3798:1 3799:1 3800:1
-1 	|BT| (FRAG (NP (NP (DT The) (NN copper) (NN chelator) (NN trientine) (JJ antiangiogenic) (NN effect)) (NP (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (ADVP (RB possibly)) (NN inhibition) (NN interleukin-8) (NN production)))) |ET| |BS|12:Z01.542.049 43:F01.145.544 104:C04.557.470.200.025.255 1084:D12.644.276.374.200.120.800 1085:D02.092.782.258.368.880 1086:D27.505.696.377.077.099 1087:D27.505.519.914.500 1088:D01.268.556.195|ES| 2:1 19:1 75:1 103:1 303:1 304:1 691:1 1548:1 2677:1 3801:1 3802:1 3803:1 3804:1 3805:1
-1 	|BT| (NP (NNS defensins) (NP (NP (NN matrilysin)) (, ,) (S (ADVP (RB highly)) (VP (VBN overexpressed) (NP (NN colon) (NN cancer)))))) |ET| |BS|937:D08.811.277.656.300.480.525.700.250 1089:D12.644.050.200|ES| 2:1 18:1 19:1 25:1 113:1 626:1 3289:1 3806:1
-1 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
-1 	|BT| (S (NP (DT The) (NN effect) (NN honokiol) (NN invasion) (NN migration) (NN breast) (NN cancer) (NN cell)) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (NNP Matrigel) (NN invasion)) (, ,) (NP (NN scratch-migration)) (, ,) (NP (NN spheroid-migration)) (, ,) (NP (NP (JJ electric) (JJ cell-substrate) (NN impedance)) (VP (VBG sensing) (NP (-LRB- -LRB-) (NP (NN ECIS) (-RRB- -RRB-) (: -)) (VBN based) (NN migration) (NN assay))))))))) |ET| |BS|225:E05.337 333:D01.045 681:G04.299.283 1090:G01.358.500.249.277.350 1091:E01.370.225.500.335 1092:G01.358.500.249 1093:F02.830.816|ES| 2:1 10:1 14:1 18:1 19:1 23:1 75:1 94:1 310:1 350:1 514:1 620:1 691:1 780:1 2895:1 3574:1 3807:1 3808:1 3809:1 3810:1 3811:1 3812:1 3813:1 3814:1
-1 	|BT| (S (NP (DT The) (JJ monoclonal) (NN antibody) (NN CH12)) (VP (VBZ augments) (NP (NP (JJ 5-fluorouracil-induced) (NN growth) (NN suppression) (JJ hepatocellular) (NN carcinoma) (NN xenograft)) (VP (VBG expressing) (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN variant) (CD III)))))) |ET| |BS|45:G07.700.320.249 92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 1094:D12.776.124.125.900 1095:A10.272.497|ES| 19:1 102:1 184:1 185:1 186:1 265:1 303:1 304:1 691:1 810:1 990:1 1365:1 2281:1 2453:1 2611:1 3815:1 3816:1 3817:1
-1 	|BT| (S (NP (NP (DT The) (NP (JJ murine) (JJ non-pancreatic) (JJ secretory) (NN phospholipase) (NN A)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN sPLA) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (-RRB- -RRB-))) (VP (VBN proposed) (NP (NP (NN tumor) (NN modifier) (JJ multiple) (JJ intestinal) (NN neoplasia)) (PRN (-LRB- -LRB-) (NP (NN Min)) (-RRB- -RRB-))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 102:C04.588.274.476.411 192:D08.811.277.352.100.680.750.937.750 608:A03.734|ES| 7:1 10:1 14:1 19:1 30:1 69:1 109:1 148:1 627:1 640:1 643:1 644:1 649:1 650:1 691:1 2129:1 3818:1 3819:1
-1 	|BT| (S (NP (DT The) (NN neurotensin) (NN receptor-1)) (VP (VBZ promotes) (NP (NN tumor) (NN development) (JJ sporadic) (JJ inflammation-associated) (NN mouse) (NN model) (NN colon) (NN cancer)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 53:C06.405.205.265 525:C23.550.470 1048:D12.776.543.750.100.550|ES| 7:1 18:1 19:1 35:1 52:1 72:1 113:1 298:1 691:1 725:1 1849:1 3657:1 3820:1
-1 	|BT| (S (NP (NP (DT The) (NN observation) (NN TKO) (NN mouse) (JJ resistant) (NN tumor)) (VP (VBG promoting) (NP (NN effect) (NN dioxin) (NN liver)))) (VP (VBZ suggests) (SBAR (S (NP (JJ inflammatory) (NN cytokine) (NN play) (JJ important) (NN step) (NN dioxin)) (VP (VBD mediated) (NP (NN liver) (NN tumor) (NN promotion) (NN mouse))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 79:I03.450.642.693 242:A03.620 429:N04.761.559.590.900 430:E05.581.249 515:C04.588.274.623 752:D12.644.276.374 1096:D03.383.231.900 1097:D03.383.231|ES| 7:1 19:1 52:1 75:1 238:1 331:1 427:1 437:1 691:1 836:1 881:1 902:1 1477:1 2087:1 2337:1 2430:1 2676:1 3821:1 3822:1
-1 	|BT| (NP (NP (NP (DT The) (NN potency) (JJ nifuroxazide) (NN breast) (NN cancer)) (VP (VBN assessed) (ADVP (FW vitro) (FW vivo))))) |ET| |BS||ES| 18:1 19:1 23:1 216:1 378:1 691:1 2796:1 2820:1 3823:1
-1 	|BT| (NP (NP (NP (DT The) (JJ potential) (NN utility) (NN acetyltanshinone) (NN IIA) (NN treatment) (JJ HER2-overexpressed) (NN breast) (NN cancer)) (: :) (NP (NP (NN Induction) (NN cancer) (NN cell) (NN death)) (VP (VBG targeting) (NP (JJ apoptotic) (JJ metabolic) (NN signaling) (NN pathway)))))) |ET| |BS|33:C04.697.098 39:G04.299.139.160 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 126:G02.111.087.800 134:G04.299.139 605:G03.495.553|ES| 18:1 19:1 23:1 94:1 104:1 195:1 383:1 411:1 546:1 616:1 691:1 827:1 2006:1 2020:1 2194:1 2195:1 2221:1 2222:1 2223:1
-1 	|BT| (S (NP (DT The) (JJ present) (NN work)) (VP (VBN conducted) (VP (VBP examine) (S (NP (NP (NN effect) (NN thymosin) (NN beta-4)) (PRN (-LRB- -LRB-) (NP (NN Tbeta4)) (-RRB- -RRB-))) (NP (NP (NN upregulation) (NN apoptosis) (NN SW480) (NN colon) (NN cancer) (NN cell)) (SBAR (S (NP (VBN induced) (NN T) (NN cell) (JJ various) (JJ chemotherapeutic) (NN agent)) (VP (VBD reduced) (NP (NP (NP (NN susceptibility) (NN cytotoxicity) (JJ anti-Fas) (NN IgM)) (PRN (-LRB- -LRB-) (NP (NN CH-11)) (-RRB- -RRB-))) (NP (JJ Tbeta4-overexpressing) (NN cell))) (ADVP (RB previously)) (VP (VBD reported) (NP (NN u))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 41:A11 68:A11.118.637.555.567.569 249:G05.355.315.800 339:G02.111.087.880 401:C23.550.291.687 445:I03.946 660:D27.505.954.248 876:F01.145 946:D27.888.569.213|ES| 10:1 14:1 18:1 19:1 75:1 89:1 94:1 113:1 412:1 452:1 691:1 728:1 960:1 993:1 1096:1 1126:1 1307:1 1353:1 1527:1 1546:1 1762:1 2243:1 3096:1 3100:1 3317:1 3824:1 3825:1 3826:1 3827:1 3828:1 3829:1 3830:1 3831:1
-1 	|BT| (S (NP (DT The) (NN result)) (VP (VBP demonstrate) (NP (NP (JJ growth-promoting) (NN property) (NN periostin)) (, ,) (NP (NP (JJ possible) (NN role)) (VP (VBG targeting) (NP (NN protein) (JJ therapeutic) (NN option) (JJ colorectal) (NN cancer))))))) |ET| |BS|4:C04.588.274.476.411.307 15:F01.829.316.616 45:G07.700.320.249 52:E02 112:D12.776.097.820|ES| 2:1 4:1 17:1 18:1 19:1 31:1 101:1 502:1 541:1 616:1 691:1 841:1 1359:1 3512:1 3832:1 3833:1
-1 	|BT| (S (NP (DT The) (NN result)) (VP (VBD demonstrated) (SBAR (S (S (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (NN Wnt2) (NN expression) (JJ cytoplasmic/nuclear) (NN beta-catenin) (NN accumulation)) (VP (VBD appeared) (NP (JJ gastric) (NN cancer) (JJ irrespective) (JJ morphological) (NN phenotype)))) (, ,) (FRAG (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (JJ over-expressed) (NN Wnt) (JJ nuclear) (NN translocalisation) (NN beta-catenin)) (VBD found) (NP (NP (ADJP (QP (CD 68) (CD 58)) (NN %)) (NN i-GCs) (CD 47) (ADJP (CD 47) (NN %)) (NN d-GCs)) (NP (ADJP (RB closely) (JJ related)) (NN pattern)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-))) (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (NP (NN co-existence) (NN Wnt2) (NN up-regulation/beta-catenin) (JJ nuclear) (NN translocalisation)) (ADJP (NP (NP (ADJP (RB positively) (VBN associated)) (NN lymph) (NN node) (NN metastasis)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.05)))) (-RRB- -RRB-))) (ADJP (RB well) (JJ T-stage))))))))) |ET| |BS|23:D12.776.091.249 80:G05.695 113:C04.697.650 142:I01.880.604 703:A10.549.400 967:D01.248.497.158.490 1042:Z01.107.757.284 1098:A11.284.430.214|ES| 2:1 10:1 14:1 18:1 19:1 37:1 60:1 86:1 98:1 101:1 115:1 148:1 169:1 236:1 260:1 311:1 312:1 315:1 369:1 419:1 691:1 787:1 806:1 855:1 862:1 877:1 1175:1 1256:1 2120:1 2536:1 2537:1 3834:1 3835:1 3836:1 3837:1 3838:1 3839:1 3840:1 3841:1 3842:1 3843:1 3844:1 3845:1 3846:1 3847:1 3848:1 3849:1 3850:1
-1 	|BT| (S (NP (DT The) (NN result) (NN study)) (VP (VBP suggest) (SBAR (S (S (NP (NP (NN E1AF)) (, ,) (NP (NP (NN expression)) (ADVP (RB closely)))) (VP (VBD correlated) (NP (NN expression) (NN matrilysin)))) (, ,) (VP (VBP play) (NP (JJ key) (NN role) (NN progression) (JJ gastric) (NN cancer))))))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 79:I03.450.642.693 937:D08.811.277.656.300.480.525.700.250|ES| 2:1 18:1 19:1 31:1 48:1 86:1 101:1 115:1 131:1 159:1 238:1 446:1 691:1 796:1 855:1 3289:1 3484:1
-1 	|BT| (S (NP (DT The) (NN result)) (VP (VBP provide) (SBAR (S (NP (NN evidence) (JJ major) (NN role) (NN beta-catenin/Apc) (NN pathway) (NN development) (JJ heterocyclic) (JJ amine-induced) (NN colon) (NN tumor)) (VP (VBP give) (NP (NN weight) (NN view) (NN regulation) (NN beta-catenin) (JJ critical) (NN tumor) (JJ suppressive) (NN effect) (NN Apc) (NN colon) (NN carcinogenesis))))))) |ET| |BS|3:C04.557.470.035.215.100 8:C04 15:F01.829.316.616 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 51:C04.588.274.476.411.307.180 142:I01.880.604 653:C23.888.144 856:D02.092|ES| 7:1 19:1 31:1 35:1 38:1 60:1 75:1 101:1 113:1 207:1 280:1 383:1 438:1 462:1 691:1 711:1 825:1 1626:1 1974:1 2399:1 3054:1 3055:1 3851:1 3852:1
-1 	|BT| (S (NP (DT The) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN MTHFR) (NN genotype) (JJ relevant) (JJ independent) (NN factor) (NN patient) (NN outcome) (JJ 5FU-based) (NN treatment)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 333:D01.045 396:G05.380 560:D03.383.742.698.875.404 606:D08.811.682.662.290|ES| 17:1 18:1 19:1 101:1 120:1 185:1 546:1 547:1 691:1 796:1 865:1 883:1 997:1 1329:1 2231:1 2232:1
-1 	|BT| (S (NP (DT The) (NNP Ron) (NN receptor) (NN tyrosine) (NN kinase)) (VP (VBD overexpressed) (NP (ADJP (RB approximately) (JJ half)) (JJ human) (NN colon) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 25:1 36:1 113:1 186:1 470:1 691:1 1843:1 2341:1 3853:1 3854:1
-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP indicate) (SBAR (S (NP (NN Wnt/beta-catenin) (NN signalling) (NN pathway)) (VP (VBD activated) (NP (JJ gastric) (NN cancer)))))) (, ,) (VP (MD may) (VP (VB play) (NP (NP (JJ pivotal) (NN role)) (NP (CC either) (NP (JJ gastric) (NN cancer) (NN formation) (NN tumour) (NN invasion) (NN dissemination)))))))) |ET| |BS|8:C04 15:F01.829.316.616 20:G03.495 23:D12.776.091.249 69:G02.111.087.800 79:I03.450.642.693|ES| 2:1 18:1 19:1 31:1 39:1 43:1 86:1 163:1 238:1 302:1 383:1 491:1 620:1 792:1 793:1 795:1 1011:1 1479:1 2437:1 3248:1
-1 	|BT| (NP (NP (DT These) (S (VP (VBG finding) (VP (VB provide) (NP (NP (JJ important) (NN information) (NN interaction)) (PP (IN among) (NP (NP (VBG transforming) (NN growth) (NN factor) (NN beta)) (, ,) (NP (NN BMP)) (, ,) (NP (NN Wnt) (NN signaling) (NN pathway) (NN progression) (NN CRC)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 16:C23.550.291.656 147:G02.149.115.800.925 503:D12.644.276.374.687 1099:D12.644.276.954.200|ES| 2:1 19:1 48:1 102:1 185:1 195:1 245:1 383:1 618:1 711:1 792:1 877:1 902:1 927:1 1372:1 1772:1 1972:1 2338:1 3855:1
-1 	|BT| (SINV (NP (DT These)) (VBG finding) (ADVP (RB strongly)) (VBP suggest) (NP (NP (NP (NN estrogen) (NN play) (JJ critical) (NN role)) (NP (JJ female) (NN hepatocarcinogenesis))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693 642:M01.975 889:D27.505.696.399.472.277|ES| 19:1 31:1 238:1 635:1 792:1 796:1 825:1 900:1 927:1 1404:1 3168:1
-1 	|BT| (S (VP (DT These) (VBG finding) (VP (VBP suggest) (S (ADVP (RB aberrantly)) (VP (VBN expressed) (SBAR (S (NP (NN CARM1) (NN tumor) (JJ marker-positive) (NN cell)) (VP (VBZ promotes) (NP (NN tumorigenesis) (JJ early) (NN stage) (NN hepatocarcinogenesis)))))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 41:A11 376:D23.101.140|ES| 6:1 7:1 19:1 78:1 94:1 298:1 792:1 796:1 900:1 927:1 1128:1 1129:1 2657:1 3856:1 3857:1
-1 	|BT| (S (NP (DT These) (NN observation)) (VP (VBP suggest) (SBAR (S (NP (JJR safer) (JJ efficacious) (NN sulindac) (NN derivative)) (VP (VBD developed) (NP (NP (JJ colorectal) (NN cancer) (NN chemoprevention)) (VP (VBG targeting) (NP (NN PDE5)) (VP (ADVP (RB possibly)) (NP (JJ cGMP-degrading) (NNS isozymes)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 251:D02.455.426.559.847.486.875 253:E02.319.162 429:N04.761.559.590.900 430:E05.581.249 993:D08.811.348 1100:D03.438.759.646.454.160 1101:N06.850.135.060.075|ES| 17:1 18:1 19:1 190:1 616:1 792:1 796:1 869:1 870:1 1165:1 1477:1 1548:1 2813:1 3858:1 3859:1 3860:1 3861:1
-1 	|BT| (S (NP (NNS Thiazolidinediones)) (VP (VBP inhibit) (NP (NN hepatocarcinogenesis) (NN hepatitis) (NN B) (JJ virus-transgenic) (NN mouse) (NN peroxisome) (JJ proliferator-activated) (NN receptor) (JJ gamma-independent) (NN regulation) (NN nucleophosmin)))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 99:B01.050.050.136.500 122:C14.280.383 142:I01.880.604 719:D12.776.826.239.588 862:D02.886.675.933 863:B04.280.375.650.425|ES| 19:1 52:1 186:1 438:1 763:1 900:1 1370:1 1801:1 1887:1 2048:1 3069:1 3070:1 3071:1 3072:1
-1 	|BT| (S (NP (DT This)) (VP (VBZ indicates) (SBAR (S (S (NP (JJ low) (NN level) (JJ active) (NN Caspase-3)) (VP (MD may) (VP (VB represent) (S (NP (NP (JJ new) (NN predictor) (NN CT) (NN responsiveness)) (, ,) (NP (NN inhibition) (NN Caspase-3)) (, ,)) (VP (VBG antagonising) (NP (JJ downstream) (NN effector) (NN Caspase-3) (NN paracrine) (NN signalling))))))) (, ,) (NP (NN COX-2)) (VP (MD may) (VP (VB improve) (NP (NP (NN patient) (NN outcome)) (VP (VBG following) (SBAR (S (NP (NNP CT)) (VP (VBD advanced) (NP (NN CRC))))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 50:M01.643 906:D08.811.277.656.262.500.126.350.300 1102:Z01.058.290.100.120 1103:G04.299.122.600|ES| 2:1 19:1 76:1 103:1 120:1 197:1 245:1 249:1 491:1 531:1 547:1 560:1 570:1 628:1 712:1 799:1 807:1 997:1 2437:1 2466:1 3190:1 3510:1 3862:1 3863:1 3864:1 3865:1 3866:1
-1 	|BT| (S (NP (DT This)) (VP (VBD led) (SBAR (S (NP (NN u)) (VP (VBP investigate) (SBAR (S (NP (NP (JJ antitumor) (NN growth)) (NP (JJ antimetastatic) (NN activity) (NN alpha-mangostin) (JJ immunocompetent) (NN xenograft) (NN model) (NN mouse) (JJ metastatic) (JJ mammary) (NN cancer) (NN p53) (NN mutation))) (VP (VBZ induces) (NP (NP (JJ metastatic) (NN spectrum)) (NP (JJ similar) (VBN seen) (JJ human) (NN breast) (NN cancer))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 10:A01.236 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 113:C04.697.650 213:F02.830.816.964 609:A01.236.249 610:G12.460|ES| 12:1 18:1 19:1 23:1 34:1 36:1 52:1 72:1 102:1 214:1 265:1 332:1 337:1 399:1 459:1 724:1 807:1 2228:1 2243:1 2244:1 2245:1 2246:1 2247:1 2248:1 2249:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (JJ NAC1-mediated) (NN autophagy)) (VP (MD may) (VP (VBN exploited) (NP (JJ new) (NN target) (VBG enhancing) (NN efficacy) (NN cisplatin) (JJ ovarian) (NN cancer) (NN type) (NN malignancy))))) |ET| |BS|390:G04.299.139.399 498:D01.210.375|ES| 2:1 18:1 19:1 49:1 160:1 491:1 543:1 712:1 1317:1 1691:1 1760:1 1761:1 1763:1 2304:1 2527:1 3867:1
-1 	|BT| (NP (NP (NNP Thymidylate) (NN synthase)) (, ,) (NP (NN thymidine) (NN phosphorylase)) (, ,) (NP (NN dihydropyrimidine) (NN dehydrogenase) (NN expression)) (, ,) (NP (JJ histological) (NN tumour) (NN regression) (JJ 5-FU-based) (JJ neo-adjuvant) (JJ chemoradiotherapy) (JJ rectal) (NN cancer))) |ET| |BS|8:C04 333:D01.045 560:D03.383.742.698.875.404 561:E02.186.079.500 713:D08.811.913.555.500.862 846:F01.393.784 869:D08.811.913.400.725.850.500 870:D08.811.682.660.350|ES| 2:1 18:1 19:1 66:1 115:1 1011:1 1986:1 1987:1 1988:1 1989:1 3002:1 3081:1 3082:1 3083:1 3084:1 3085:1 3086:1
-1 	|BT| (S (NP (JJ Tolfenamic) (NN acid)) (ADVP (RB also)) (VP (VP (VBD facilitated) (NP (NP (NN translocation) (JJ endogenous) (JJ exogenous) (NN ESE-1) (NN nucleus)) (JJ colorectal) (NN cancer) (NN cell) (, ,) (NN gene) (NN silencing)) (S (VP (VBG using) (NP (NN ESE-1) (JJ small) (VBG interfering) (NN RNA))))) (VP (VBD attenuated) (NP (ADJP (JJ tolfenamic) (JJ acid-induced)) (NN EGR-1) (NN expression) (NN apoptosis))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 42:G05.355.315.203.374 117:D13.150.650.700 463:C23.550.210.870 580:D12.776.260.158.500 1104:A11.284.430.106|ES| 2:1 5:1 9:1 17:1 18:1 19:1 89:1 94:1 100:1 115:1 350:1 515:1 750:1 808:1 1275:1 1618:1 2598:1 2599:1 3019:1 3868:1 3869:1 3870:1 3871:1 3872:1 3873:1 3874:1
-1 	|BT| (NP (NP (NN Transcription) (NN coactivator) (JJ PBP/MED1-deficient) (NNS hepatocytes)) (NP (JJ susceptible) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 209:G02.111.087.847 262:A11.436.348 554:D02.654.442.200 1105:D05.500.374.750|ES| 19:1 52:1 894:1 899:1 900:1 2732:1 2991:1 3875:1 3876:1
-1 	|BT| (S (NP (NP (VBG Transforming) (NN growth) (NN factor-beta) (NN adaptor)) (, ,) (NP (NN beta2-spectrin)) (, ,)) (VP (VBZ modulates) (S (NP (NN cyclin) (JJ dependent) (NN kinase) (CD 4)) (VP (VB reduce) (NP (NN development) (JJ hepatocellular) (NN cancer)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 503:D12.644.276.374.687 1106:D08.811.913.696.620.682.700.646.500.875 1107:D12.776.124.875|ES| 2:1 18:1 19:1 35:1 102:1 303:1 319:1 321:1 470:1 606:1 743:1 1773:1 2361:1 3877:1 3878:1 3879:1
-1 	|BT| (S (NP (JJ Transgenic) (NN mouse) (VBG expressing) (NN cyclooxygenase-2) (NNS hepatocytes)) (VP (VBP reveal) (NP (JJ minor) (NN contribution) (NN enzyme) (NN chemical) (NN hepatocarcinogenesis)))) |ET| |BS|24:D08.811.600.720.750 99:B01.050.050.136.500 262:A11.436.348 730:D08.811 1108:M01.416|ES| 19:1 52:1 61:1 810:1 894:1 900:1 1360:1 1670:1 2124:1 2388:1 3880:1 3881:1
-1 	|BT| (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (NN Loss) (NN E-cadherin)) (PRN (-LRB- -LRB-) (NP (NN CDH1)) (-RRB- -RRB-))) (, ,) (NP (NN Smad4)) (, ,) (NP (NP (NN p53) (VBN shown) (NN play) (JJ integral) (NN role)) (ADJP (JJ gastric))) (, ,) (NP (JJ intestinal) (, ,) (NN breast) (NN cancer) (NN formation)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 12:Z01.542.049 15:F01.829.316.616 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 70:A03.556.875.875 79:I03.450.642.693 613:D12.776.395.550.200.200|ES| 2:1 10:1 12:1 14:1 18:1 19:1 23:1 31:1 43:1 86:1 104:1 109:1 237:1 238:1 521:1 1788:1 2266:1 2267:1 2268:1 2269:1
-1 	|BT| (S (PP (IN Unlike) (NP (NN celecoxib))) (, ,) (NP (NN sulindac)) (VP (VBD proved) (NP (ADJP (RB highly) (JJ effective)) (NN colon) (NN tumor) (NN prevention) (NN 15-PGDH) (NN KO) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 51:C04.588.274.476.411.307.180 251:D02.455.426.559.847.486.875 684:D02.065.884.247|ES| 2:1 7:1 19:1 52:1 113:1 133:1 626:1 869:1 1474:1 1639:1 2179:1 2807:1 2849:1 3882:1
-1 	|BT| (S (NP (NP (NN Up-regulation) (JJ several) (NN miR-1) (NN target)) (PP (VBG including) (NP (NP (NN FoxP1)) (, ,) (NP (NN MET)) (, ,) (NP (NN HDAC4) (JJ primary) (JJ human) (NNS HCCs) (NP (NN down-regulation) (NN expression) (JJ 5-AzaC-treated) (NN HCC) (NN cell)))))) (VP (VBP suggest) (NP (NN role) (NN hepatocarcinogenesis)))) |ET| |BS|15:F01.829.316.616 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880|ES| 2:1 19:1 31:1 36:1 94:1 115:1 160:1 257:1 262:1 344:1 441:1 561:1 796:1 900:1 957:1 1132:1 2270:1 2271:1 2272:1 2273:1 2274:1
-1 	|BT| (S (NP (JJ Ursodeoxycholic) (NN acid)) (VP (VBZ inhibits) (NP (NP (NN Ras) (NN mutation)) (, ,) (NP (NP (JJ wild-type) (NN Ras)) (NN activation)) (, ,) (NP (NN cyclooxygenase-2) (NN expression) (NN colon) (NN cancer))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 24:D08.811.600.720.750 122:C14.280.383 737:D04.808.105.225.272.962|ES| 2:1 8:1 18:1 19:1 34:1 61:1 113:1 115:1 225:1 615:1 1275:1 1775:1 3121:1
-1 	|BT| (S (S (NP (JJ Ursolic) (NN acid)) (VP (VBZ inhibits) (NP (NP (NN growth) (NN metastasis) (JJ human) (JJ colorectal) (NN cancer) (JJ orthotopic) (JJ nude) (NN mouse) (NN model)) (VP (VBG targeting) (NP (JJ multiple) (NN cell) (NN signaling) (NN pathway)))))) (: :) (NP (NN chemosensitization) (NN capecitabine))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 113:C04.697.650 122:C14.280.383 126:G02.111.087.800 810:D03.383.742.680.245.500.425|ES| 17:1 18:1 19:1 36:1 52:1 72:1 94:1 102:1 104:1 195:1 266:1 383:1 615:1 616:1 649:1 806:1 1275:1 2873:1 3740:1 3883:1 3884:1
-1 	|BT| (S (NP (NNP Use) (JJ novel) (JJ genetic) (NN mouse) (NN model)) (VP (VBP investigate) (NP (NN role) (NN folate) (JJ colitis-associated) (NN colon) (NN cancer)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 53:C06.405.205.265 224:D03.438.733.631.400 259:D12.776.395.240.150.500 1109:E05.599.395.397|ES| 18:1 19:1 31:1 52:1 72:1 113:1 410:1 459:1 778:1 864:1 891:1 3885:1
-1 	|BT| (S (S (VP (VBG Using) (NP (JJ protein-protein) (NN interaction) (NN screening)))) (, ,) (VP (VBD found) (SBAR (S (NP (NN FOXO3a)) (VP (VBD interacted) (NP (NN ER-alpha) (NN ER-beta) (NN protein) (JJ human) (NN breast) (NN carcinoma) (NN cell) (NN line) (NN MCF-7)) (, ,) (S (VP (VBG suggesting) (VP (VBZ exists) (NP (NN crosstalk) (NN FOXO3a) (NN ER) (NN signaling) (NN pathway) (JJ estrogen-dependent) (NN breast) (NN cancer) (NN cell)))))))))) |ET| |BS|7:D12.776 126:G02.111.087.800 148:G12.425.143.281 432:A11.251.210.190.630 889:D27.505.696.399.472.277 1110:D12.776.826.750.350.174 1111:D12.776.826.750.350.262 1112:D23.125|ES| 2:1 4:1 18:1 19:1 23:1 36:1 37:1 94:1 195:1 224:1 264:1 304:1 383:1 618:1 741:1 1009:1 1188:1 1484:1 1719:1 3361:1 3362:1 3363:1 3886:1 3887:1 3888:1 3889:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD shown) (SBAR (S (NP (NN Hsp90) (NN inhibitor) (NN 17-AAG)) (VP (VBZ enhances) (NP (NN cytotoxicity) (NN oxaliplatin) (NN colon) (NN cancer) (NN cell) (NN line) (NN inhibition) (NN NF-kappaB))))))) |ET| |BS|43:F01.145.544 94:A11.251.210 210:D12.776.260.600 946:D27.888.569.213 1113:D12.776.580.216.380|ES| 18:1 19:1 94:1 103:1 113:1 237:1 264:1 380:1 714:1 843:1 1356:1 2543:1 3317:1 3890:1 3891:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (S (NP (NN HT-29) (JJ human) (NN colon) (NN adenocarcinoma) (NN cell) (NN effect)) (VP (NN NO-ASA) (NP (NP (JJ inducible) (NN form) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN NOS2)) (-RRB- -RRB-))))) (, ,) (NN enzyme) (VBN implicated) (NN colon) (NN carcinogenesis)))) |ET| |BS|22:D08.811.682.664.500.772.500 33:C04.697.098 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 84:C04.557.470.200.025 189:V02.460 670:D02.455.426.559.389.657.410.595.176 730:D08.811 792:A11.251.210.190.475 1114:D08.811.277.352.827.070.250|ES| 2:1 10:1 14:1 19:1 36:1 63:1 64:1 65:1 66:1 75:1 94:1 113:1 207:1 255:1 324:1 630:1 843:1 977:1 2388:1 2782:1 3892:1 3893:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (NP (NP (NP (JJ antiangiogenic) (NN effect) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN copper) (NN chelator) (NN trientine)) (, ,) (S (VP (ADVP (RB especially)) (VBG focusing) (NP (NP (NN relationship) (NN copper) (NN interleukin-8)) (PRN (-LRB- -LRB-) (NP (NN IL-8)) (-RRB- -RRB-)))) (, ,) (NP (JJ potent) (JJ angiogenic) (NN factor)) (VP (VBN produced) (NP (NN hepatoma) (NN cell))))))) |ET| |BS|41:A11 104:C04.557.470.200.025.255 515:C04.588.274.623 1084:D12.644.276.374.200.120.800 1085:D02.092.782.258.368.880 1086:D27.505.696.377.077.099 1087:D27.505.519.914.500 1088:D01.268.556.195 1115:D27.505.696.377.077.077 1116:G14.640.079|ES| 2:1 10:1 14:1 19:1 22:1 75:1 94:1 134:1 185:1 223:1 303:1 304:1 324:1 345:1 441:1 843:1 3790:1 3801:1 3802:1 3803:1 3804:1 3805:1 3894:1 3895:1 3896:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (NN effect) (NN pioglitazone) (NN lung) (NN cancer) (NN development) (JJ carcinogen-induced) (NN lung) (NN adenocarcinoma) (NP (NP (JJ squamous) (NN cell) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN SCC)) (-RRB- -RRB-)))))) |ET| |BS|279:D27.888.569.100 929:C04.557.470.200.400|ES| 10:1 14:1 18:1 19:1 35:1 75:1 94:1 255:1 304:1 324:1 328:1 843:1 1067:1 2421:1 3897:1 3898:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (SBAR (S (NP (NP (NP (NN role) (NN Se) (NNS selenoproteins) (NN liver) (NN tumor) (NN formation)) (NN TGFalpha/c-Myc) (JJ transgenic) (NN mouse)) (, ,) (NP (VBN characterized) (VBN disrupted) (NN redox) (NN homeostasis))) (VP (VBP develop) (NP (NN liver) (NN cancer) (CD 6) (NN month) (NN age))))))) |ET| |BS|15:F01.829.316.616 20:G03.495 99:B01.050.050.136.500 152:G07.700.345 515:C04.588.274.623 522:D12.644.276.382.750 865:G02.149.767.650 1073:D12.776.864 1117:Z01.639.520.750|ES| 2:1 7:1 18:1 19:1 31:1 43:1 52:1 285:1 324:1 500:1 648:1 836:1 843:1 985:1 2039:1 2723:1 3075:1 3529:1 3899:1 3900:1 3901:1 3902:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD found) (FRAG (NP (NN melatonin)) (ADVP (RB significantly)) (NP (VBD enhanced) (NP (JJ 5-FU-mediated) (NN inhibition) (NN cell) (NN proliferation)) (, ,) (NP (NP (NN colony) (NN formation)) (, ,) (NP (NN cell) (NN migration) (NN invasion) (NN colon) (NN cancer) (NN cell))))))) |ET| |BS|20:G03.495 41:A11 43:F01.145.544 109:I01.696.116 183:G04.299.233.750 560:D03.383.742.698.875.404 681:G04.299.283 707:D03.438.473.914.481|ES| 2:1 18:1 19:1 37:1 43:1 94:1 103:1 113:1 124:1 299:1 314:1 385:1 514:1 620:1 843:1 2556:1 3903:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD found) (SBAR (S (NP (NP (NN treatment) (JJ COX2-overexpressing) (NN HT29) (JJ human) (NN colon) (NN cancer) (NN cell) (NN fisetin)) (PRN (-LRB- -LRB-) (NP (CD 30-120) (NN microM)) (-RRB- -RRB-))) (VP (VBD resulted) (SBAR (S (NP (NP (NN induction) (NN apoptosis)) (, ,) (NP (NP (NN downregulation) (NN COX2) (NN protein) (NN expression)) (PP (IN without) (S (VP (VBG affecting) (NP (NN COX1))))))) (VP (VBD inhibited) (NP (NN secretion) (NN prostaglandin) (NN E2)))))))))) |ET| |BS|7:D12.776 39:G04.299.139.160 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 122:C14.280.383 792:A11.251.210.190.475 1118:D10.251.355.255.550.250.200 1119:D08.811.600.720.500 1120:A12.200|ES| 2:1 4:1 10:1 14:1 18:1 19:1 36:1 37:1 89:1 94:1 113:1 115:1 365:1 546:1 594:1 595:1 736:1 843:1 1195:1 2084:1 2530:1 2978:1 3017:1 3685:1 3904:1 3905:1 3906:1 3907:1 3908:1 3909:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD examined) (NP (NP (NP (NP (NP (NP (NN toxicity)) (FW vivo) (NP (NN efficacy) (NN lead) (NN diaminothiazole) (NN 4-Amino-5-benzoyl-2)) (: -)) (PRN (-LRB- -LRB-) (NP (JJ 4-methoxy) (NN phenylamino)) (-RRB- -RRB-))) (NN thiazole)) (PRN (-LRB- -LRB-) (NP (NN DAT1)) (-RRB- -RRB-))) (NN colon) (NN cancer) (NN xenograft)))) |ET| |BS|86:D01.268.556.435 92:E04.936.764 93:A01.941.875 1121:D02.886.675|ES| 5:1 10:1 14:1 18:1 19:1 113:1 254:1 265:1 324:1 378:1 843:1 2304:1 2406:1 3910:1 3911:1 3912:1 3913:1 3914:1 3915:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBN shown) (NP (NP (NN I3C) (JJ cyclic) (JJ tetrameric) (JJ derivative) (NN CTet)) (VP (VBN formulated) (NP (NP (NN gamma-cyclodextrin)) (PRN (-LRB- -LRB-) (NP (NN gamma-CD)) (-RRB- -RRB-))) (ADVP (RB efficiently)) (VP (VBD inhibited) (NP (JJ cellular) (NN proliferation) (NN breast) (NN cancer) (NN cell) (NN line))))))) |ET| |BS|41:A11 122:C14.280.383 776:G01.910.645 1122:B01.050.500.500.294.700.750.700.680|ES| 10:1 14:1 18:1 19:1 23:1 94:1 237:1 264:1 299:1 365:1 772:1 843:1 2813:1 3074:1 3916:1 3917:1 3918:1 3919:1 3920:1 3921:1 3922:1 3923:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD hypothesized) (S (NP (NN PTK6) (NN inhibition) (JJ effective) (NN strategy)) (VP (VBP inhibit) (SBAR (S (NP (NP (NP (NP (NN growth) (NN survival) (NN Her2)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (NN breast) (NN cancer) (NN cell)) (, ,) (PP (VBG including) (NP (ADJP (RB relatively) (JJ resistant)) (NNP Lapatinib))) (, ,)) (VP (VBN targeted) (NP (NP (NP (NP (NN therapy) (NN Her2)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (NN breast) (NN cancer)) (, ,) (NP (CC either) (ADJP (RB intrinsically) (VBN acquired)) (JJ continuous) (NN drug) (NN exposure)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 43:F01.145.544 45:G07.700.320.249 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 67:D26 96:I03.784 122:C14.280.383|ES| 2:1 10:1 14:1 16:1 18:1 19:1 23:1 39:1 94:1 102:1 103:1 130:1 191:1 274:1 427:1 561:1 843:1 1041:1 1044:1 1114:1 1370:1 1639:1 1750:1 1953:1 3059:1 3924:1 3925:1 3926:1 3927:1 3928:1
-1 	|BT| (S (NP (PRP We)) (VP (VP (VBD investigated) (NP (NP (NN colon) (NN cancer) (NN cell) (NN effect)) (NP (NN geraniol) (NN thymidylate) (NN synthase) (NN thymidine) (NN kinase) (NN expression)))) (, ,) (NP (CD two) (NN enzyme) (JJ related) (NN 5-fluorouracil) (NN cytotoxicity)))) |ET| |BS|41:A11 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862 730:D08.811 946:D27.888.569.213 1123:D08.811.913.696.620.750|ES| 2:1 18:1 19:1 66:1 75:1 94:1 113:1 115:1 403:1 419:1 470:1 843:1 933:1 2307:1 2388:1 2578:1 3082:1 3317:1 3929:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (NP (NN expression) (NN leptin) (NN receptor) (CD 171) (JJ consecutive) (NN patient)) (PRN (-LRB- -LRB-) (NP (NP (CD 78) (JJ female) (CD 93) (NN male)) (: ;) (NP (CD 71) (NN year))) (-RRB- -RRB-))) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 642:M01.975 1124:D06.472.699.042.500|ES| 10:1 14:1 19:1 115:1 120:1 186:1 217:1 245:1 403:1 843:1 1402:1 1404:1 1452:1 3206:1 3930:1 3931:1 3932:1 3933:1 3934:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (S (NP (JJ suppressive) (NN effect) (NN roxithromycin)) (VP (VBD accelerated) (NP (JJ hepatocellular) (NN carcinoma) (NN growth) (NN rat) (JJ hepatocarcinogenetic) (NN model)) (NP (VBN compared) (NN result) (NN effect) (NN TNP-470))))))) |ET| |BS|45:G07.700.320.249 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 843:D02.540.576.500.992.630|ES| 19:1 50:1 72:1 75:1 101:1 102:1 303:1 304:1 403:1 843:1 849:1 1391:1 1974:1 2990:1 3935:1 3936:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NN lack) (NN fucosylation) (JJ consequent) (NN loss) (NN GDP-fucose) (NN synthesis)) (VP (VBZ contributes) (NP (NN colon) (NN carcinogenesis))))))) |ET| |BS|20:G03.495 33:C04.697.098 46:A03.556.124.526.356 1125:D03.438.759.646.454.340.350.400|ES| 19:1 32:1 113:1 207:1 221:1 252:1 403:1 843:1 845:1 3436:1 3937:1 3938:1 3939:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD demonstrated) (SBAR (S (NP (NN simvastatin)) (VP (VBZ inhibits) (NP (NP (NN NF-kappaB)) (SBAR (S (NP (NN signaling) (JJ human) (JJ intestinal) (JJ epithelial) (NN cell)) (VP (VBZ ameliorates) (NP (JJ acute) (JJ murine) (NN colitis))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 47:A03.556.124 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 75:A11.436 122:C14.280.383 210:D12.776.260.600 754:D02.455.426.559.847.638.400.900|ES| 19:1 36:1 90:1 94:1 109:1 127:1 143:1 195:1 615:1 627:1 714:1 843:1 1175:1 1527:1 2679:1 2877:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD showed) (SBAR (S (NP (NP (NP (NP (JJ anthocyanin-containing) (JJ baked) (JJ purple-fleshed) (NN potato)) (PRN (-LRB- -LRB-) (NP (NN PP)) (-RRB- -RRB-))) (NN extract)) (PRN (-LRB- -LRB-) (NP (NN PA)) (-RRB- -RRB-))) (VP (VBD suppressed) (SBAR (S (NP (JJ early) (JJ advanced) (JJ human) (NN colon) (NN cancer) (NN cell) (NN proliferation)) (VP (VBD induced) (NP (NP (NN apoptosis)) (, ,) (NP (NP (NN effect) (NN colon) (NNS CSCs)) (ADJP (VBN known)))))))))))) |ET| |BS|39:G04.299.139.160 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 183:G04.299.233.750 556:C11.768.175 667:B01.650.940.800.575.100.905.725.777 668:B01.650.940.800.575.100.905.725.777 669:D03.383.663.283.266.450.087 1126:Z01.639.760.590.715 1127:Z01.107.757.656|ES| 2:1 10:1 14:1 18:1 19:1 36:1 75:1 89:1 94:1 113:1 132:1 299:1 307:1 412:1 556:1 843:1 997:1 1128:1 1527:1 1966:1 2439:1 2440:1 2496:1 3940:1 3941:1 3942:1 3943:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD showed) (SBAR (S (NP (NN embelin)) (VP (VBZ inhibits) (NP (NN growth) (NN colon) (NN cancer) (NN cell) (NN vitro))))) (, ,) (VP (ADVP (RB effectively)) (VBZ suppresses) (NP (JJ 1,2-dimethylhydrazine) (JJ dihydrochloride-induced) (NN colon) (NN carcinogenesis) (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383|ES| 2:1 18:1 19:1 52:1 94:1 102:1 113:1 132:1 207:1 216:1 615:1 686:1 843:1 1527:1 2642:1 2889:1 2977:1 3145:1
-1 	|BT| (S (NP (PRP We)) (VBP suggest) (NP (NN inosine) (CD 5)) ('' ') (: -) (NP (NP (NN monophosphate) (NN dehydrogenase) (NN inhibitor)) (, ,) (VP (ADVP (RB already)) (VBN used) (NP (NN treatment) (NN disease)))) (, ,) (VP (MD may) (NP (VBN used) (JJ potential) (NN differentiation) (NN therapy) (NN drug) (NN control) (NN prostate) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 74:G04.299.151 288:C23.550.288 1128:D08.811.682.047.820.450 1129:E02.319|ES| 2:1 18:1 19:1 77:1 130:1 191:1 215:1 289:1 380:1 476:1 491:1 546:1 796:1 827:1 843:1 998:1 3085:1 3944:1 3945:1 3946:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD tested) (S (NP (NP (NP (NN role) (JJ basic) (NN fibroblast) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN bFGF)) (-RRB- -RRB-))) (NP (JJ vascular) (NP (NP (JJ endothelial) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN VEGF)) (-RRB- -RRB-))))) (VP (VBP switch) (NP (JJ angiogenic) (NN phenotype)) (NP (CD 35) (NN patient) (JJ colorectal) (NN cancer) (JJ different) (NN stage) (NN disease)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 80:G05.695 288:C23.550.288 371:A07.231 1067:D12.644.276.624.120 1130:D12.644.276.390|ES| 10:1 14:1 17:1 18:1 19:1 31:1 102:1 120:1 185:1 236:1 414:1 843:1 998:1 1129:1 1251:1 2066:1 2213:1 2709:1 2988:1 3092:1 3733:1 3790:1 3947:1 3948:1
-1 	|BT| (SINV (IN While) (NP (JJ exact) (NN mechanism)) (-LRB- -LRB-) (S (NP (-RRB- -RRB-) (NN antitumor) (NN activity) (NN p-XSC)) (VP (VBZ remains) (VP (VBN elucidated)))) (, ,) (VP (VBZ appears)) (NP (NP (NN modulation) (NN beta-catenin) (NN expression) (NN COX-2) (NN activity)) (VBN associated) (NN inhibition) (JJ intestinal) (NN polyp))) |ET| |BS|23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 193:C23.300.825.411|ES| 2:1 10:1 14:1 19:1 60:1 76:1 103:1 109:1 115:1 162:1 169:1 399:1 442:1 647:1 1945:1 2244:1 3949:1 3950:1 3951:1 3952:1 3953:1
-1 	|BT| (S (NP (NP (NN Zinc-finger) (NN protein) (CD 331)) (, ,) (NP (JJ novel) (JJ putative) (NN tumor) (NN suppressor)) (, ,)) (VP (VBZ suppresses) (NP (NN growth) (NN invasiveness) (JJ gastric) (NN cancer)))) |ET| |BS|7:D12.776 45:G07.700.320.249 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500 1131:G02.111.570.820.709.600.040.985|ES| 2:1 4:1 7:1 18:1 19:1 86:1 102:1 686:1 700:1 891:1 918:1 3954:1 3955:1 3956:1
1 	|BT| (NP (NP (JJ Possible) (NN involvement) (JJ oxidative) (NN stress) (JJ fenofibrate-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 916:D02.241.081.114.968.500.625|ES| 19:1 636:1 849:1 900:1 2522:1 2583:1 4333:1 4334:1
1 	|BT| (S (NP (JJ Possible) (NN involvement) (JJ oxidative) (NN stress) (NN piperonyl) (NN butoxide)) (VP (VBD induced) (NP (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 1077:D03.383.246.118.600|ES| 19:1 412:1 636:1 849:1 900:1 2522:1 2583:1 3777:1 3778:1 4333:1
1 	|BT| (S (NP (NNP Prevention) (JJ azoxymethane/dextran) (NN sodium) (JJ sulfate-induced) (NN mouse) (NN colon) (NN carcinogenesis)) (VP (VBN processed) (NP (NNP Aloe) (NN vera) (NN gel)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080|ES| 19:1 52:1 113:1 207:1 405:1 407:1 674:1 2898:1 4025:1 4026:1 4027:1 4335:1
1 	|BT| (NP (NP (JJ Protective) (NN effect) (NN dioscin) (JJ alcohol-induced) (NN liver) (NN injury))) |ET| |BS|242:A03.620 751:D02.033.375 822:D02.033|ES| 19:1 75:1 836:1 2416:1 2672:1 2909:1 2910:1
1 	|BT| (NP (NP (NP (NP (NN ra) (NN proto-oncogene) (NN activation) (JJ dichloroacetic) (NN acid)) (: -) (, ,) (NP (NN trichloroethylene)) (: -)) (JJ tetrachloroethylene-induced) (NN liver) (NN tumor) (NN B6C3F1) (NN mouse))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 11:B01.050.150.900.649.865.635.505.500 235:G05.360.340.024.340.375.500.791 515:C04.588.274.623 1219:D02.241.081.018.214.500 1235:D02.455.526.439.939 1236:D02.455.526.439.880|ES| 2:1 7:1 19:1 52:1 225:1 563:1 836:1 1115:1 3986:1 4273:1 4336:1 4337:1 4338:1
1 	|BT| (S (NP (NNS Rats)) (VP (VBD received) (SBAR (S (NP (NP (JJ weekly) (JJ intraperitoneal) (NN injection) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBD followed) (NP (NP (JJ 2-week) (JJ wash-out) (NN period)) (VP (VBD caused) (NP (NP (NN cirrhosis) (CD 14) (NN week)) (JJ multifocal) (NN HCC) (CD 18) (NN week))))))))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 554:D02.654.442.200 662:C23.550.355 776:G01.910.645 917:E02.319.267.530.490|ES| 10:1 14:1 19:1 441:1 783:1 785:1 1199:1 1440:1 1875:1 1952:1 2506:1 2725:1 3130:1 3230:1 3266:1 3664:1 3714:1 4076:1 4339:1 4340:1 4341:1
1 	|BT| (NP (NP (VBN Reduced) (NP (NN susceptibility) (JJ azoxymethane-induced) (JJ aberrant) (NN crypt) (NN focus) (NN formation) (NN colon) (NN cancer) (NN growth) (NN hormone) (JJ deficient) (NN rat)))) |ET| |BS|20:G03.495 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 401:C23.550.291.687 824:C04.834.020 1237:D06.472.699.631.525.425.875 1238:D06.472.699.631.525.425|ES| 18:1 19:1 43:1 102:1 113:1 542:1 849:1 1353:1 1431:1 1504:1 1531:1 1725:1 2533:1 2913:1
1 	|BT| (NP (NP (NN Regulation) (NN iron) (JJ metabolism-related) (NN gene) (JJ diethylnitrosamine-induced) (NN mouse) (NN liver) (NN tumor))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 140:G05.355.315 515:C04.588.274.623 554:D02.654.442.200 895:D01.490.600 896:D01.268.556.412 898:G03.495|ES| 7:1 9:1 19:1 52:1 699:1 836:1 2732:1 3162:1 4342:1
1 	|BT| (S (S (NP (NN Reporter) (NN mouse) (VBN given) (NN azoxymethane)) (VP (VBD followed) (S (NP (NN dextran) (NN sulfate) (NN sodium)) (VP (VBP induce) (NP (NN colitis) (NN colon) (NN tumor)))))) (: ;) (S (NP (NN mouse)) (VP (VBN given) (NP (NNP ROCK) (NN inhibitor) (NN fasudil)) (PP (IN along) (NP (NP (NN agent)) (PRN (-LRB- -LRB-) (NP (NN ROCK) (NN inhibitor) (NN increase) (NN miRNA) (NN function)) (-RRB- -RRB-))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 53:C06.405.205.265 131:D09.698.365.272.300 132:D02.172.080 184:D13.150.650.319|ES| 7:1 10:1 14:1 19:1 29:1 33:1 40:1 52:1 113:1 143:1 217:1 243:1 380:1 406:1 407:1 728:1 840:1 1993:1 2666:1 3130:1 3300:1 4343:1 4344:1 4345:1
1 	|BT| (S (NP (NNS Results) (NN study)) (VP (VBP demonstrate) (SBAR (S (NP (NP (NN PPARalpha)) (VP (VBN required))) (VP (VBP mediate) (NP (NP (NN hepatocarcinogenesis) (VBD induced) (NN bezafibrate)) (, ,) (S (NP (NN PPARalpha)) (VP (VBZ protects) (NP (JJ potential) (NN cholestasis)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 535:H01.770.644.145.431 536:D12.776.826.239.500 879:C06.130.120.135 909:D02.065.277.067|ES| 2:1 19:1 131:1 412:1 502:1 702:1 827:1 900:1 1176:1 1601:1 1863:1 3201:1 4115:1 4131:1
1 	|BT| (NP (NP (NNS RESULTS) (: :)) (UCP (S (NP (NN Deletion) (NN Tgfbr2) (NN liver) (JJ epithelial) (NN cell)) (VP (VBP alter) (NP (NN liver) (NN injury)))) (, ,) (NP (NP (JJ toxin-induced) (JJ biliary) (NN fibrosis)) (, ,) (NP (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis))))) |ET| |BS|242:A03.620 262:A11.436.348 306:G05.355.600.800 554:D02.654.442.200 691:C23.550.355 1239:A12.200.087 1240:D23.946|ES| 2:1 19:1 94:1 104:1 127:1 710:1 836:1 900:1 949:1 2416:1 2732:1 4152:1 4346:1 4347:1 4348:1 4349:1
1 	|BT| (S (NP (NNS RESULTS) (: :)) (NP (NN Silibinin) (NN feeding)) (VP (VBD showed) (NP (NP (ADJP (NP (JJ dose-dependent) (NN decrease) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis)) (JJR stronger)) (NN efficacy) (NN pretreatment)) (CC versus) (NP (NN posttreatment) (NNS regimen))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 532:E02.183|ES| 19:1 78:1 104:1 113:1 132:1 295:1 710:1 1881:1 1983:1 2304:1 2531:1 2533:1 2824:1 2942:1 2943:1 2944:1 2945:1
1 	|BT| (S (NP (NNS RESULTS)) (: :) (S (NP (PRP We)) (VP (VBD uncovered) (SBAR (S (NP (NN adrenaline)) (VP (VBD promoted) (NP (JJ DEN-induced) (NN hepatocarcinogenesis))))))) (, ,) (VP (VBD reversed) (NP (NN ADRB2) (NN antagonist) (NN ICI118) (CD ,551)))) |ET| |BS|1241:D12.776.543.750.069.300.300.340.200 1242:D02.033.100.291.310|ES| 2:1 19:1 104:1 710:1 843:1 900:1 1271:1 1912:1 2735:1 4350:1 4351:1 4352:1 4353:1 4354:1
1 	|BT| (NP (NP (NN Role) (NN CYP2E1) (JJ diethylnitrosamine-induced) (FW hepatocarcinogenesis) (FW vivo))) |ET| |BS|15:F01.829.316.616 554:D02.654.442.200 1218:D08.244.453.300|ES| 19:1 378:1 900:1 2187:1 2732:1 4270:1
1 	|BT| (NP (NP (NN Role) (NN Nrf2) (JJ oxidative) (NN stress) (JJ fenofibrate-induced) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|15:F01.829.316.616 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 799:D12.776.260.615.249 916:D02.241.081.114.968.500.625|ES| 19:1 849:1 900:1 2187:1 2522:1 2583:1 4334:1 4355:1
1 	|BT| (NP (NP (NN Role) (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor-alpha)) (PRN (-LRB- -LRB-) (NP (NN PPARalpha)) (-RRB- -RRB-))) (JJ bezafibrate-induced) (NN hepatocarcinogenesis) (NN cholestasis))) |ET| |BS|15:F01.829.316.616 536:D12.776.826.239.500 879:C06.130.120.135 909:D02.065.277.067|ES| 10:1 14:1 19:1 900:1 1801:1 1887:1 1889:1 2187:1 4115:1 4131:1 4356:1
1 	|BT| (NP (NP (NP (NP (NN Role) (NN life) (NN span) (NN determinant) (NN P66)) (PRN (-LRB- -LRB-) (NP (NN shcA)) (-RRB- -RRB-))) (JJ ethanol-induced) (NN liver) (NN damage))) |ET| |BS|15:F01.829.316.616 242:A03.620 751:D02.033.375 1243:K01.752.400|ES| 10:1 14:1 19:1 836:1 1848:1 2187:1 2674:1 4357:1 4358:1 4359:1 4360:1 4361:1
1 	|BT| (S (ADVP (RB Second)) (, ,) (NP (NN carbon) (NN tetrachloride)) (-LRB- -LRB-) (NP (NP (NP (NN CCl) (-LRB- -LRB-) (CD 4) (-RRB- -RRB-)) (: ;) (NP (NP (NP (CD 0.2) (NN ml/kg)) (, ,) (NP (JJ 2/week) (NN ip))) (VP (VBG starting) (NP (CD 8) (NN week) (NN age)))) (-RRB- -RRB-)) (VP (VBN administered) (NP (CD 9) (CD 14) (NN week)))) (VP (VBP develop) (NP (JJ advanced) (NN liver) (NN fibrosis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 113:C04.697.650 676:C06.552.630 1025:Z01.252.100.450 1217:A02.513.514.100 1220:D02.455.526.439.150|ES| 2:1 10:1 14:1 19:1 217:1 319:1 648:1 781:1 783:1 836:1 949:1 997:1 1440:1 2336:1 2717:1 3902:1 4261:1 4278:1 4279:1 4362:1 4363:1 4364:1 4365:1 4366:1
1 	|BT| (NP (NP (NP (JJ Selective) (NN pressure) (NN tumor) (NN promotion)) (NP (JJ phenobarbital) (NN lead) (JJ clonal) (NN outgrowth) (JJ beta-catenin-mutated) (NN mouse) (NN liver) (NN tumor)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 86:D01.268.556.435 301:A11.251.353 515:C04.588.274.623 756:D03.383.742.698.253.650 1244:G01.374.715|ES| 7:1 19:1 52:1 254:1 836:1 1069:1 2337:1 2685:1 4031:1 4367:1 4368:1 4369:1
1 	|BT| (S (NP (NP (CD SP600125)) (, ,) (NP (NN JNK) (NN inhibitor)) (, ,)) (VP (VBD reported) (NP (NN block) (JJ acetaminophen-induced) (NN liver) (NN injury)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 122:C14.280.383 242:A03.620 661:D02.065.199.092.040|ES| 2:1 19:1 380:1 742:1 836:1 993:1 2411:1 2416:1 4113:1 4276:1
1 	|BT| (S (NP (DT The) (NN parameter)) (NP (JJ related) (JJ key) (NN event) (JJ Metofluthrin-induced) (NN liver) (NN tumor)) (VP (VBD observed) (NP (JJ tumorigenic) (NN dose) (NN level)))) |ET| |BS|515:C04.588.274.623|ES| 7:1 19:1 159:1 205:1 249:1 261:1 419:1 691:1 836:1 1809:1 2301:1 4370:1 4371:1
1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP examine) (NP (NP (NP (JJ anti-cancer) (JJ anti-fibrotic) (NN effect) (NN BCAA) (NN development) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VBN induced) (NN HCC) (NN liver) (NN cirrhosis) (NN rat) (NN model)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 554:D02.654.442.200 691:C23.550.355|ES| 10:1 14:1 19:1 35:1 72:1 75:1 131:1 409:1 441:1 691:1 836:1 849:1 960:1 1112:1 1199:1 1567:1 1875:1 1952:1 2360:1 4372:1
